search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


A randomized trial comparing longstanding indwelling pleural catheters with pleurodesis as a frontline treatment for malignant pleural effusion.


- candidate number8463
- NTR NumberNTR2518
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR16-sep-2010
- Secondary IDsNL32135.031.10 CCMO
- Public TitleA randomized trial comparing longstanding indwelling pleural catheters with pleurodesis as a frontline treatment for malignant pleural effusion.
- Scientific TitleA randomized trial comparing longstanding indwelling pleural catheters with pleurodesis as a frontline treatment for malignant pleural effusion.
- ACRONYMIPC vs talc pleurodesis
- hypothesisThe observed improvement in palliative care (dyspnoea is the most prominent symptom) in the pleurodesis group is less than the improvement in the indwelling arm.
- Healt Condition(s) or Problem(s) studiedMalignant pleural effusion, IPC (indwelling pleural catheter), Talc pleurodesis
- Inclusion criteria1. Symptomatic pleural effusion;
2. Any histologically or cytologically proven malignancy;
3. Written informed consent;
4. Recurrence of pleural effusion within 6 months after last therapeutic thoracentesis.
- Exclusion criteria1. Other causes of pleural effusion than malignancy;
2. Previous chemical or surgical pleurodesis;
3. Impaired immunity: Leucopenia <2.0 x 109/L, high dose corticosteriods (>=1 mg/kg);
4. Thrombocytopenia (<50 x 109/L).
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-jul-2010
- planned closingdate1-jul-2012
- Target number of participants120
- Interventions1. Thoracentesis;
2. Talc pleurodesis;
3. Placement of indwelling pleural catheter.
- Primary outcomePatient reported dyspnoea at 4 to 6 weeks after the intervention, assessed by th Modified Borg scale.
- Secondary outcome1. Number of emergency presentations at the outpatient clinic for reasons of symptomatic MPE after completion of the treatment;
2. Number of interventions for MPE after completion of the MPE treatment;
3. The overall time of hospitalization because of MPE;
4. Patient reported dyspnoea and thoracic pain, directly following catheter placement and 3 and 6 months after randomization;
5. Quality of Life;
6. The treatment outcome at 1,3 and 6 months;
7. Overall treatment costs in relation to MPE;
8. Adverse Events;
9. Overall survival;
10. Detection of prognostic markers for the outcome of the intervention;
11. Development of a clinical decision rule for treatment of MPE.
- Timepoints1. First patient in 2010 Q3;
2. Final patient in 2012 Q1;
3. Data lock 2012 Q3;
4. Reporting 2013 Q1.
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESDr. M.M. Heuvel, van den
- CONTACT for SCIENTIFIC QUERIESDr. M.M. Heuvel, van den
- Sponsor/Initiator Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI AVL)
- Funding
(Source(s) of Monetary or Material Support)
- PublicationsA final report will be prepared for publication in peer reviewed journals.
Authorship will include investigators who have recruited at least 10% of the total number of evaluable patients and investigators who participated significantly to the translational research.
The authors sequence should usually reflect the input (like the number of evaluable patients enrolled) of/by the respective investigator.
Draft versions of abstracts or manuscripts must be made available to the co-authors before any presentation of results or submission for publication.
- Brief summaryConsecutive 120 patients with symptomatic MPE will be registered in part 1 (thoracentesis) of the study. 80 patients (of the 120) with recurrent symptomatic MPE will be asked to participate in a randomized trial comparing the standard talc pleurodesis (arm A) with the experimental treatment, the indwelling catheter (arm B). Primairy endpoint of the study is the patient reported dyspnoea at 4 to 6 weeks after the intervention, assessed by the Modified Bord scale.
- Main changes (audit trail)
- RECORD16-sep-2010 - 26-sep-2010


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl